Actively Recruiting
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Led by Miltenyi Biomedicine GmbH · Updated on 2024-11-20
150
Participants Needed
5
Research Sites
811 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
CONDITIONS
Official Title
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study.
- Provided written informed consent to participate in this study.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Stanford University
Stanford, California, United States, 94305
Actively Recruiting
2
Yale University
New Haven, Connecticut, United States, 06520
Actively Recruiting
3
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States, 21201
Not Yet Recruiting
4
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
5
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Actively Recruiting
Research Team
S
Sadie Swift
CONTACT
P
Paris Jamiel
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here